Drug
Empagliflozin
Empagliflozin: highest development phase Approved, developed by Boehringer Ingelheim. 2 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| SYNJARDY | Approved | |
| Empagliflozin NCT07107945 | Phase 3 | Chronic Kidney Disease |
Latest
- Exclusivity ends 2026-12-20 (application 206111)
Follow Empagliflozin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.